Platelet-Type von Willebrand Disease: Toward an Improved Understanding of the “Sticky Situation”

Maha Othman; Jonas Emsley

doi:10.1055/s-0033-1364182

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2014; 40(02): 146-150
DOI: 10.1055/s-0033-1364182

Editorial Focus

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Platelet-Type von Willebrand Disease: Toward an Improved Understanding of the “Sticky Situation”

Maha Othman

¹Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada

²Health Sciences, St Lawrence College, Kingston, Ontario, Canada

,

Jonas Emsley

³School of Pharmacy, Centre for Biomolecular Sciences, University of Nottingham, Nottingham, United Kingdom

› Author Affiliations

Abstract

Full Text

References

References
1 Woods AI, Sanchez-Luceros A, Bermejo E , et al. Identification of p.W246L as a novel mutation in the GP1BA gene responsible for platelet-type von Willebrand disease [In Focus Article]. Semin Thromb Hemost 2014; 40 (2) 151-160
2 Othman M. Platelet-type von Willebrand disease and type 2B von Willebrand disease: a story of nonidentical twins when two different genetic abnormalities evolve into similar phenotypes. Semin Thromb Hemost 2007; 33 (8) 780-786
3 Favaloro EJ. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin?. Semin Thromb Hemost 2008; 34 (1) 113-127
4 Favaloro EJ. 2B or not 2B? Differential identification of type 2B, versus pseudo-von Willebrand disease. Br J Haematol 2006; 135 (1) 141-142 , author reply 143
5 Favaloro EJ, Bonar R, Meiring M, Street A, Marsden K ; RCPA QAP in Haematology. 2B or not 2B? Disparate discrimination of functional VWF discordance using different assay panels or methodologies may lead to success or failure in the early identification of type 2B VWD. Thromb Haemost 2007; 98 (2) 346-358
6 Favaloro EJ, Koutts J. 2B or not 2B? Masquerading as von Willebrand disease? Journal of thrombosis and haemostasis. J Thromb Haemost 2012; 10 (2) 317-319
7 Favaloro EJ, Patterson D, Denholm A , et al. Differential identification of a rare form of platelet-type (pseudo-) von Willebrand disease (VWD) from Type 2B VWD using a simplified ristocetin-induced-platelet-agglutination mixing assay and confirmed by genetic analysis. Br J Haematol 2007; 139 (4) 623-626
8 Giannini S, Cecchetti L, Mezzasoma AM, Gresele P. Diagnosis of platelet-type von Willebrand disease by flow cytometry. Haematologica 2010; 95 (6) 1021-1024
9 Hamilton A, Ozelo M, Leggo J , et al. Frequency of platelet type versus type 2B von Willebrand disease. An international registry-based study. Thromb Haemost 2011; 105 (3) 501-508
10 Rydz N, James PD. The evolution and value of bleeding assessment tools. J Thromb Haemost 2012; 10 (11) 2223-2229
11 Kaur H, Scovil S, McEacern K, James P, Othman M. International systematic study for assessment of bleeding phenotype in platelet type von Willebrand disease. Paper presented at: 26th Congress of the International Society on Thrombosis and Haemostasis; June 29–July 4, 2013; Amsterdam, The Netherlands
12 Othman M, Favaloro EJ. Genetics of type 2B von Willebrand disease: “true 2B,” “tricky 2B,” or “not 2B.” What are the modifiers of the phenotype?. Semin Thromb Hemost 2008; 34 (6) 520-531
13 Wagner DD, Fay PJ, Sporn LA, Sinha S, Lawrence SO, Marder VJ. Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells. Proc Natl Acad Sci U S A 1987; 84 (7) 1955-1959
14 Haberichter SL, Budde U, Obser T, Schneppenheim S, Wermes C, Schneppenheim R. The mutation N528S in the von Willebrand factor (VWF) propeptide causes defective multimerization and storage of VWF. Blood 2010; 115 (22) 4580-4587
15 Haberichter SL, Jacobi P, Montgomery RR. Critical independent regions in the VWF propeptide and mature VWF that enable normal VWF storage. Blood 2003; 101 (4) 1384-1391
16 Montgomery RR, Zimmerman TS. von Willebrand's disease antigen II. A new plasma and platelet antigen deficient in severe von Willebrand's disease. J Clin Invest 1978; 61 (6) 1498-1507
17 Borchiellini A, Fijnvandraat K, ten Cate JW , et al. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood 1996; 88 (8) 2951-2958
18 Madabhushi SR, Shang C, Dayananda KM , et al. von Willebrand factor (VWF) propeptide binding to VWF D'D3 domain attenuates platelet activation and adhesion. Blood 2012; 119 (20) 4769-4778
19 Casonato A, Gallinaro L, Cattini MG , et al. Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia. Haematologica 2010; 95 (8) 1366-1372
20 Othman M. Differential identification of PT-VWD from type 2B VWD and GP1BA nomenclature issues. Br J Haematol 2008; 142 (2) 312-314 , author reply 314–315
21 Goodeve AC, Reitsma PH, McVey JH ; Working Group on Nomenclature of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Nomenclature of genetic variants in hemostasis. J Thromb Haemost 2011; 9 (4) 852-855
22 Miller JL, Cunningham D, Lyle VA, Finch CN. Mutation in the gene encoding the alpha chain of platelet glycoprotein Ib in platelet-type von Willebrand disease. Proc Natl Acad Sci U S A 1991; 88 (11) 4761-4765
23 Moriki T, Murata M, Kitaguchi T , et al. Expression and functional characterization of an abnormal platelet membrane glycoprotein Ib alpha (Met239 —> Val) reported in patients with platelet-type von Willebrand disease. Blood 1997; 90 (2) 698-705
24 Matsubara Y, Murata M, Sugita K, Ikeda Y. Identification of a novel point mutation in platelet glycoprotein Ibalpha, Gly to Ser at residue 233, in a Japanese family with platelet-type von brand disease. J Thromb Haemost 2003; 1 (10) 2198-2205
25 Enayat S, Ravanbod S, Rassoulzadegan M , et al. A novel D235Y mutation in the GP1BA gene enhances platelet interaction with von Willebrand factor in an Iranian family with platelet-type von Willebrand disease. Thromb Haemost 2012; 108 (5) 946-954
26 Othman M, Notley C, Lavender FL , et al. Identification and functional characterization of a novel 27-bp deletion in the macroglycopeptide-coding region of the GPIBA gene resulting in platelet-type von Willebrand disease. Blood 2005; 105 (11) 4330-4336
27 Uff S, Clemetson JM, Harrison T, Clemetson KJ, Emsley J. Crystal structure of the platelet glycoprotein Ib(alpha) N-terminal domain reveals an unmasking mechanism for receptor activation. J Biol Chem 2002; 277 (38) 35657-35663
28 Dumas JJ, Kumar R, McDonagh T , et al. Crystal structure of the wild-type von Willebrand factor A1-glycoprotein Ibalpha complex reveals conformation differences with a complex bearing von Willebrand disease mutations. J Biol Chem 2004; 279 (22) 23327-23334
29 Huizinga EG, Tsuji S, Romijn RA , et al. Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science 2002; 297 (5584) 1176-1179
30 Dong J, Schade AJ, Romo GM , et al. Novel gain-of-function mutations of platelet glycoprotein IBalpha by valine mutagenesis in the Cys209-Cys248 disulfide loop. Functional analysis under statis and dynamic conditions. J Biol Chem 2000; 275 (36) 27663-27670
31 Murata M, Russell SR, Ruggeri ZM, Ware J. Expression of the phenotypic abnormality of platelet-type von Willebrand disease in a recombinant glycoprotein Ib alpha fragment. J Clin Invest 1993; 91 (5) 2133-2137
32 Nurden P, Lanza F, Bonnafous-Faurie C, Nurden A. A second report of platelet-type von Willebrand disease with a Gly233Ser mutation in the GPIBA gene. Thromb Haemost 2007; 97 (2) 319-321
33 Takahashi H, Nagayama R, Hattori A, Ihzumi T, Tsukada T, Shibata A. Von Willebrand disease associated with familial thrombocytopenia and increased ristocetin-induced platelet aggregation. Am J Hematol 1981; 10 (1) 89-99